Milestone: Indication under evaluation

Dipraglurant is a novel orally available highly selective metabotropic glutamate receptor subtype 5 negative allosteric modulator (mGlu5 NAM) which has completed Phase 1 and demonstrated efficacy in a Phase 2a proof of concept study for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID).

Therapeutic indications
Type of product
  • Phase
    Phase II started
  • Partnering status
    Not partnered

You may also be interested in